Gabay C., Emery P., van Vollenhoven R., Dikranian A., Alten R., Pavelka K., Klearman M., Musselman D., Agarwal S., Green J., Kavanaugh A.: Tocilizumab monotherapy is Superior to adalimumab monotherapy in reducing disease activity in patients with rheumatoid arthritis (ADACTA) : results from a randomized double-blind trial. Lancet 2013; 381: 1541-1550

Lauper K., Nordström D.C., Pavelka K., Hernandez M.V., Kvien T.K., kristianlund E.K., Santos M.J., Rotar Z., Iannone F., Codreanu C., Lukina G., Gale S., Sarsour K., Luder Y., Courvoisier D.S., Gabay C.: Comparative effectiveness of tocilizumab versus TNF inhibitors as monotherapy or in combination with conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis after the use of at least one biologic disease-modifying antirheumatic drug : analysis from the pan-european TOCERRA register collaboration. Ann Rheum Dis 2018; 77 :1276-82

Girard-Guyonvarc’h C., Palomo J., Martin P., Rodriguez E., Troccaz S., Palmer G., Gabay C.: Unopposed IL-18 signaling leads to severe TLR9-induced macrophage activation syndrome in mice. Blood 2018; 131: 1430-1441

Gabay C., Fautrel B., Rech J., Spertini F., Feist E., Kötter I., Morel J., Schaeverbeke T., Hamidou M.A., Martin T., Hellmich B., Lamprecht P., Schulze-Koops H., Courvoisier D.S., sleight A., Schiffrin E.J.: Open-label muticenter, dose-escalating phase II clinical trial on the safety and efficacy of tadekinig alfa (IL-18BP) in adult-onset Still’s disease. Ann Rheum Dis 2018; 77: 840-847

Vigne S., Palmer G., Martin P., Lamacchia C., Strebel D., Rodriguez E., Olleros M.L., Vesin D., Garcia I., Ronchi F., Sallusto F., Sims J.E., Gabay C.: IL-36 Signaling Amplifies Th1 Responses by Enhancing Proliferation and Th1 Polarization of Naïve CD4+ T cells. Blood 2012; 120: 3478-87
H-index: 89 (Google scholar), publication number 553, Citations (without self-citations): 46,860